《2022年國(guó)際立場(chǎng)聲明： 人血白蛋白在肝硬化相關(guān)并發(fā)癥治療中的應(yīng)用》摘譯

打開文本圖片集

摘要：近期，來自19個(gè)國(guó)家的33名具有肝硬化相關(guān)并發(fā)癥管理專業(yè)知識(shí)的研究人員經(jīng)過三輪德爾菲法提出了12項(xiàng)有關(guān)人血白蛋白在肝硬化相關(guān)并發(fā)癥治療中應(yīng)用的國(guó)際立場(chǎng)聲明。本文對(duì)該部國(guó)際立場(chǎng)聲明的主要內(nèi)容進(jìn)行中文摘譯。關(guān)鍵詞：肝硬化； 血清白蛋白， 人； 共識(shí)

An excerpt of use of albumin infusion for cirrhosis-related complications： an international position statement in 2022

BAI Zhaohui YANG Yongping YANG Li QI Xingshun（1. Department of Gastroenterology， General Hospital of Northern Theater Command， Shenyang， China; 2. Department of Hepatology， The Fifth Medical Center of Chinese PLA General Hospital， Beijing， China; 3. Department of Gastroenterology， West China Hospital， Sichuan University， Chengdu， China）

Corresponding author：QI Xingshun， [email protected] （ORCID：0000-0002-9448-6739）

Abstract：Recently， 33 investigators from 19 countries with expertise in managing cirrhosis-related complications have proposed 12 international position statements regarding the use of human albumin infusion for cirrhosis-related complications after a three-round Delphi consensus process. This article gives an excerpt of the main contents of this international position statement in Chinese language.

Key words：Liver Cirrhosis; Serum Albumin， Human; Consensus

肝硬化是威脅人類生命健康的重大疾病，其在全世界范圍內(nèi)廣泛流行并給各國(guó)造成了沉重的醫(yī)療負(fù)擔(dān)。（剩余1674字）